Suchergebnisse - "Thomson, Rachel"

PubPharm (5)

1

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

enthalten in: The Lancet. Oncology | 2018

von Maio, M. | Lewis, K. | Demidov, L. | +113

CommentIn: Lancet Oncol. 2018 Apr;19(4):436-437. - PMID 29477664

2

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients : Guidelines from Australian melanoma medical oncologists

enthalten in: Asia-Pacific journal of clinical oncology | 2016

von Atkinson, V. | Long, G. | Menzies, A. | +8

3

Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy

enthalten in: Scientific reports | 2015

von Sepulveda, P. | Lamon, S. | Hagg, A. | +6

4

The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass

enthalten in: The Journal of cell biology | 2013

von Winbanks, C. | Chen, J. | Qian, H. | +12

5

Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin

enthalten in: The Journal of cell biology | 2012

von Winbanks, C. | Weeks, K. | Thomson, R. | +11

1
[1]